Synthesis and carbonic anhydrase I, II, IV and XII inhibitory properties of N-protected amino acid - sulfonamide conjugates

Journal of Enzyme Inhibition and Medicinal Chemistry
F Zehra KüçükbayClaudiu T Supuran

Abstract

N-protected amino acids (Gly, Ala and Phe protected with Boc and Z groups) were reacted with sulfonamide derivatives, leading to the corresponding N-protected amino acid-sulfonamide conjugates. The carbonic anhydrase (CA, EC 4.2.1.1) inhibitory activity of the new compounds was assessed against four human (h) isoforms, hCA I, hCA II, hCA IV and hCA XII. Among them, hCA II, IV and XII are antiglaucoma drug targets, being involved in aqueous humor secretion within the eye. Low nanomolar inhibition was measured against all four isoforms with the 20 reported sulfonamides, but no selective inhibitory profiles, except for some CA XII-selective derivatives, were observed. hCA I, II and XII were generally better inhibited by sulfonamides incorporating longer scaffolds and Gly/Ala, whereas the best hCA IV inhibitors were homosulfanilamide derivatives, incorporating Phe moieties. The amino acid-sulfonamide conjugates show good water solubility and effective hCA II, IV and XII inhibition, and may be considered as interesting candidates for antiglaucoma studies.

References

May 1, 1990·Transactions of the Royal Society of Tropical Medicine and Hygiene·W Trager
Dec 25, 2002·Medicinal Research Reviews·Claudiu T SupuranAngela Casini
Jan 3, 2008·Nature Reviews. Drug Discovery·Claudiu T Supuran
Feb 12, 2009·Journal of the American Chemical Society·Alfonso MarescaClaudiu T Supuran
Jun 10, 2010·Bioorganic & Medicinal Chemistry Letters·Claudiu T Supuran
Jul 23, 2011·Frontiers in Pharmacology·Claudiu T Supuran
Sep 17, 2011·Nature Reviews. Drug Discovery·Dario Neri, Claudiu T Supuran
Nov 15, 2011·Journal of Medicinal Chemistry·Nadia TouisniClaudiu T Supuran
Dec 23, 2011·Journal of Enzyme Inhibition and Medicinal Chemistry·Cemalettin AlpClaudiu T Supuran
Dec 24, 2011·Expert Opinion on Therapeutic Patents·Fabrizio CartaAndrea Scozzafava
Dec 24, 2011·Journal of Inorganic Biochemistry·Giuseppina De Simone, Claudiu T Supuran
Feb 4, 2012·Journal of Enzyme Inhibition and Medicinal Chemistry·Adeline BonneauClaudiu T Supuran
Feb 4, 2012·Journal of Enzyme Inhibition and Medicinal Chemistry·Alfonso MarescaClaudiu T Supuran
Feb 4, 2012·Journal of Enzyme Inhibition and Medicinal Chemistry·Alfonso MarescaClaudiu T Supuran
Feb 18, 2012·Expert Opinion on Emerging Drugs·Claudiu T Supuran
Apr 4, 2012·Journal of Enzyme Inhibition and Medicinal Chemistry·Claudiu T Supuran
Nov 24, 2012·Journal of Enzyme Inhibition and Medicinal Chemistry·Deniz EkinciClaudiu T Supuran
Feb 6, 2013·Journal of Enzyme Inhibition and Medicinal Chemistry·Claudiu T Supuran
Mar 16, 2013·Journal of Enzyme Inhibition and Medicinal Chemistry·Aditi SharmaClaudiu T Supuran
Mar 16, 2013·Expert Opinion on Therapeutic Patents·Fabrizio Carta, Claudiu T Supuran
Mar 19, 2013·Chemical Biology & Drug Design·Siva S PandaAlan R Katritzky
Apr 24, 2013·Expert Opinion on Therapeutic Patents·Andrea ScozzafavaFabrizio Carta
May 1, 2013·Expert Opinion on Drug Discovery·Giuseppina De SimoneClaudiu T Supuran
May 1, 2013·Journal of Enzyme Inhibition and Medicinal Chemistry·Clemente Capasso, Claudiu T Supuran
May 1, 2013·Expert Opinion on Therapeutic Patents·Emanuela MasiniClaudiu T Supuran
May 16, 2013·Expert Opinion on Therapeutic Patents·Simona Maria MontiGiuseppina De Simone
Aug 7, 2013·Journal of Enzyme Inhibition and Medicinal Chemistry·Sonia Del PreteClemente Capasso
Jan 25, 2014·Journal of Enzyme Inhibition and Medicinal Chemistry·Sonia Del PreteClemente Capasso
Mar 29, 2014·Journal of Enzyme Inhibition and Medicinal Chemistry·Alaa A-M Abdel-AzizClaudiu T Supuran
Apr 29, 2014·Journal of Enzyme Inhibition and Medicinal Chemistry·Clemente Capasso, Claudiu T Supuran
Jul 10, 2014·Journal of Enzyme Inhibition and Medicinal Chemistry·Viviana De LucaClemente Capasso
Oct 28, 2014·Journal of Enzyme Inhibition and Medicinal Chemistry·Erik O PettersenDan Cojocari
Nov 20, 2014·Chemical Communications : Chem Comm·Katia D'AmbrosioGiuseppina De Simone
Nov 29, 2014·Journal of Enzyme Inhibition and Medicinal Chemistry·Alexandre Le DarzSébastien Thibaudeau
Dec 17, 2014·Expert Opinion on Therapeutic Targets·Claudiu T Supuran, Clemente Capasso
Mar 15, 2015·Bioorganic & Medicinal Chemistry·Fabrizio CartaClaudiu T Supuran
Jul 15, 2015·Expert Review of Neurotherapeutics·Claudiu T Supuran
Aug 11, 2015·Organic & Biomolecular Chemistry·Mohamed A IbrahimAlan R Katritzky
Sep 4, 2015·The Journal of Pharmacology and Experimental Therapeutics·Mohamed BejaouiJoan Rosselló-Catafau

❮ Previous
Next ❯

Citations

Nov 15, 2017·Archiv der Pharmazie·Umit M KocyigitMustafa Ceylan
Jun 15, 2017·Journal of Biochemical and Molecular Toxicology·Umit M KocyigitMustafa Ceylan
May 26, 2018·Metabolites·Niccolò ChiaramonteClaudiu T Supuran
Jan 10, 2020·Journal of Enzyme Inhibition and Medicinal Chemistry·Hasan KüçükbayClaudiu T Supuran

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.